Why the study?
Hemolytic anemia can occur late after cardiac valve replacement, requiring evaluation of medical therapy versus invasive intervention.
Highlights that severe hemolytic anemia can occur >20 years post-prosthetic mitral valve replacement and can potentially be managed medically.
Answers are grounded in this paper and cite their sources.
Medical management may be viable for late hemolytic anemia after valve replacement; case report leaves open need for larger studies.
Hemolytic anemia is a well-known complication of prostheses following the replacement of cardiac valves. Therefore, in all patients with prosthetic valve placement who present with anemia or hyperbilirubinemia, hemolysis is an important differential that must be ruled out, irrespective of how long the valve replacement has lasted. Indications for repair either through percutaneous or surgical approach generally include the severity of hemolysis based on either persistent symptoms of fatigue, the continued requirement of blood transfusions, or else the progression of valvular dysfunction. However, if hemoglobin remains stable, symptoms resolve, there is minimal functional impairment, or the risk of comorbidities is greater than the benefits of invasive intervention, then an initial trial of medical therapy is prudent. Our case report is unique as it demonstrates the late occurrence of symptomatic severe hemolytic anemia more than 20 years after valvular replacement. It also offers an alternative approach to invasive management in patients who develop this complication after such a prolonged asymptomatic period.
No takes yet. Share an insight, caveat, or question.
Kaur et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: